IRX Therapeutics
New York
About IRX Therapeutics
IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $127.7M
- Funding stage: M&A
- Last round: Series Unknown (Aug 2017)
- Website: brooklynitx.com
- Phone: (212) 582-1199
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/irx-therapeutics-130418 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.